Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity Active Not Recruiting Phase 1 / 2 Trials for Fludeoxyglucose F-18 (DB09502)

IndicationStatusPhase
DBCOND0029503 (Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity)Active Not Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT0180667518F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyDiagnostic